Eaton Vance Management Travere Therapeutics, Inc. Transaction History
Eaton Vance Management
- $67.5 Billion
- Q3 2022
A detailed history of Eaton Vance Management transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Eaton Vance Management holds 121,514 shares of TVTX stock, worth $2.48 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
121,514
Previous 121,514
-0.0%
Holding current value
$2.48 Million
Previous $2.94 Million
1.7%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TVTX
# of Institutions
213Shares Held
94.3MCall Options Held
1.2MPut Options Held
778K-
Black Rock Inc. New York, NY7.64MShares$156 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.36MShares$150 Million1.81% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.74MShares$137 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.97MShares$101 Million3.46% of portfolio
-
Macquarie Group LTD Australia, C34.26MShares$86.8 Million0.09% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.31B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...